Delaware Healthcare FundTM

Objective

Delaware Healthcare Fund seeks maximum long-term capital growth through capital appreciation.

Strategy

The Fund typically invests in companies that develop, produce, or distribute products related to the healthcare or medical industries and derive a substantial portion of their sales from products and services in the healthcare industry. The fund invests in U.S. and non-U.S. companies across all market capitalizations.

Fund information
Inception date09/28/2007
Dividends paid*Annually
Capital gains paid*December

*If any.

Fund identifiers
NASDAQDLHIX
CUSIP24610E408

Institutional Class shares are only available to certain investors. See the prospectus for more information. 

The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance quoted.

Total returns may reflect waivers and/or expense reimbursements by the manager and/or distributor for some or all of the periods shown. Performance would have been lower without such waivers and reimbursements.

Average annual total return as of month-end (03/31/2014)
YTD1 year3 year5 year10 yearLifetimeInception date
NAV (view definition)7.41%37.97%22.21%30.87%n/a20.37%09/28/2007
Russell 3000 Healthcare Index5.77%30.56%23.36%22.68%n/an/a
Average annual total return as of quarter-end (03/31/2014)
QTDYTD1 year3 year5 year10 yearLifetimeInception date
NAV (view definition)7.41%7.41%37.97%22.21%30.87%n/a20.37%09/28/2007
Russell 3000 Healthcare Index5.77%5.77%30.56%23.36%22.68%n/an/a

Returns for less than one year are not annualized.

Prior to January 28, 2010, the Fund had not engaged in a broad distribution effort of its shares and had been subject to limited redemption requests. The returns reflect expense limitations that were in effect during certain periods and which may have been lower than the Fund's current expenses. The returns would have been lower without expense limitations.

Expense ratio
Gross1.13%
Net1.13%
Quarterly total returns @ NAV
Year1st quarter2nd quarter3rd quarter4th quarterAnnual return
20147.41%n/an/an/an/a
201317.54%8.81%9.89%7.43%50.98%
201218.59%-5.47%3.28%3.07%19.34%
20119.26%4.49%-15.90%7.33%3.06%
20107.96%-12.31%10.96%10.53%16.10%
2009-2.72%20.44%22.95%11.97%61.31%
2008-7.00%1.91%4.63%-12.08%-12.81%
2007n/an/an/a2.66%n/a

Institutional Class shares are only available to certain investors. See the prospectus for more information. 

Portfolio characteristics - as of 03/31/2014
Share assets$131.2 million
Number of holdings67
Market cap (median)$8.36 billion
Market cap (weighted average)$44.89 billion
Portfolio turnover (last fiscal year)29%
P/E ratio (weighted average FY1) (view definition)19.66x
Beta (relative to Russell 3000 Healthcare Index) (view definition)1.14
Annualized standard deviation, 3 years (view definition)15.46
Portfolio composition as of 03/31/2014Total may not equal 100% due to rounding.
Domestic equities72.2%
International equities & depository receipts31.0%
Cash and cash equivalents-3.2%
Top 10 holdings as of 03/31/2014
Holdings are as of the date indicated and subject to change.
List excludes cash and cash equivalents.
Holding% of portfolio
Eli Lilly & Co.8.1%
Teva Pharmaceutical Industries Ltd.6.9%
WellPoint Inc.5.6%
UCB S.A.5.0%
Quest Diagnostics Inc.4.5%
Pfizer Inc.3.3%
Bristol-Myers Squibb Co.3.3%
Chugai Pharmaceutical Co. Ltd.3.1%
SINA Corp/China3.0%
News Corp.3.0%
Total % Portfolio in Top 10 holdings45.8%

Holdings are as of the date indicated and subject to change.

Top sectors as of 03/31/2014
List excludes cash and cash equivalents.
Sector% of portfolio
Blue Chip Medical Products45.4%
Healthcare Services22.8%
Other16.1%
Biotechnology13.1%
Small/Mid - Cap Medical Products5.6%
Medical Distributors0.2%
Distribution history - annual distributions (Institutional Class)
Distributions ($ per share)
YearCapital gainsDividends
20140.0000.000
20130.4200.000
20120.0000.065
20110.7550.031
20100.6510.033
20091.2800.022
20080.3400.007
20070.3010.000
20060.0000.000
20050.0000.000
20040.0000.000

Institutional Class shares are only available to certain investors. See the prospectus for more information. 

Liu-Er Chen

Liu-Er Chen, CFA

Chief Investment Officer — Emerging Markets and Healthcare

Start date on the Fund: September 2007

(View bio)


Institutional Class shares are only available to certain investors. See the prospectus for more information. 

Shareholder fees
Maximum sales charge (load) imposed on purchases as a percentage of offering pricenone
Maximum contingent deferred sales charge (load) as a percentage of original purchase price or redemption price, whichever is lowernone
Annual fund operating expenses
Management fees0.85%
Distribution and service (12b-1) feesnone
Other expenses0.28%
Total annual fund operating expenses1.13%
Fee waivers and expense reimbursementsnone
Total annual fund operating expenses after fee waivers and expense reimbursements1.13%

Institutional Class shares are only available to certain investors. See the prospectus for more information. 

Carefully consider the Fund's investment objectives, risk factors, charges, and expenses before investing. This and other information can be found in the Fund's prospectus and its summary prospectus, which may be obtained by clicking the prospectus link located in the right-hand sidebar or calling 800 362-7500. Investors should read the prospectus and the summary prospectus carefully before investing.

Investing involves risk, including the possible loss of principal.

Narrowly focused investments may exhibit higher volatility than investments in multiple industry sectors.

Healthcare companies are subject to extensive government regulation and their profitability can be affected by restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure, and malpractice or other litigation.

International investments entail risks not ordinarily associated with U.S. investments including fluctuation in currency values, differences in accounting principles, or economic or political instability in other nations.

Investing in emerging markets can be riskier than investing in established foreign markets due to increased volatility and lower trading volume.

Investments in small and/or medium-sized companies typically exhibit greater risk and higher volatility than larger, more established companies.

“Nondiversified” funds may allocate more of their net assets to investments in single securities than “diversified” Funds. Resulting adverse effects may subject these Funds to greater risks and volatility.

The Funds are distributed by Delaware Distributors L.P., an affiliate of Delaware Management Holdings, Inc., and Macquarie Group Limited.

Not FDIC Insured | No Bank Guarantee | May Lose Value

Fund Finder

Daily pricing (as of 04/23/2014)

Institutional ClassPriceNet changeYTD
NAV$18.93-0.154.70%
Max offer price$18.93n/an/a

Total net assets (as of 03/31/2014)

$397.7 million all share classes

Lipper ranking (as of 03/31/2014)

YTD ranking15 / 88
1 year38 / 86
3 years41 / 77
5 years3 / 70
10 yearsn/a
Lipper classificationHealth/Biotech Funds

(View Lipper disclosure)

Literature

Prospectuses and reports

Benchmark, peer group

Russell 3000® Healthcare Index (view)

Lipper Health/Biotechnology Funds Average (view)

Additional information